COVID-19 patients who develop a cytokine storm in response to infection could be unable to produce memory cells that provide long-term protection against SARS-CoV-2.
Browsing: Basic > Immunology
A research team from The Rosalind Franklin Institute, Diamond Light Source, The University of Oxford and Public Health England have engineered nanobodies from llama antibodies that show protective immune effects against SARS-CoV-2.
Researchers have accurately profiled the immune response to COVID-19 in critically ill patients, allowing them to identify six inflammatory molecules as potential targets for COVID-19 treatment.
In this interview we speak to José Javier García from Pivotal about his company´s involvement in a large-scale clinical trial testing the safety and efficacy of hyperimmune convalescent plasma treatment in COVID-19 patients.
Researchers at the Emory Vaccine Center have demonstrated that a novel adjuvant, 3M-052, can aid long-lasting immunity against HIV in rhesus monkeys. This could have implications for developing successful vaccines against HIV, influenza and COVID-19.
Take a look behind the scenes of a recent Future Virology paper, titled ‘Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection: Let the…
Researchers at Scripps Research Institute have used the blood of recovered COVID-19 patients to identify potent antibodies that protect against SARS-CoV-2. The study, published in Science, has shown the antibodies’ successful use in animal models and human cell cultures.
Researchers have repurposed cancer immunotherapy tools to identify regions of SARS-CoV-2 to target with a vaccine. They believe the use of this strategy could help develop a vaccine that provides long-term protection from COVID-19.
The largest trial to date assessing the use of convalescent plasma therapy for COVID-19 has revealed that the treatment is effective in 76% of patients, with no adverse effects. Further research is needed to evaluate how to optimize this therapy.